title: A phase I study of lenalidomide in combination with fludarabine and rituximab in previously untreated CLL/SLL.
authors.forename: J R
authors.initials: JR
authors.lastname: Brown
authors.forename: J
authors.initials: J
authors.lastname: Abramson
authors.forename: E
authors.initials: E
authors.lastname: Hochberg
authors.forename: E
authors.initials: E
authors.lastname: Mikler
authors.forename: V
authors.initials: V
authors.lastname: Dalton
authors.forename: L
authors.initials: L
authors.lastname: Werner
authors.forename: H
authors.initials: H
authors.lastname: Reynolds
authors.forename: C
authors.initials: C
authors.lastname: Thompson
authors.forename: S M
authors.initials: SM
authors.lastname: McDonough
authors.forename: Y
authors.initials: Y
authors.lastname: Kuang
authors.forename: J
authors.initials: J
authors.lastname: Ritz
authors.forename: D
authors.initials: D
authors.lastname: Neuberg
authors.forename: A S
authors.initials: AS
authors.lastname: Freedman
mesh_terms: D000328:Adult; D000368:Aged; D000410:Alanine Transaminase / Q000097:blood; D058846:Antibodies, Monoclonal, Murine-Derived / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D001219:Aspartate Aminotransferases / Q000097:blood; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000097:blood / Q000188:drug therapy* / Q000201:enzymology; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000139:chemically induced; D000069283:Rituximab; D013921:Thrombocytopenia / Q000139:chemically induced; D014740:Vidarabine / Q000009:adverse effects / Q000031:analogs & derivatives*
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D014740:Vidarabine; C024352:fludarabine